The drugs that made GLP-1s famous were tested on weight, not PCOS — so a monthly symptom log is the only record that tells you whether your PCOS is actually responding. Track ten symptoms plus a waist measurement on the first of each month, and bring the trend to your clinician.
Why weight is the lever — and what it isn’t
Semaglutide and tirzepatide drive weight loss by slowing gastric emptying and acting on appetite circuits in the hypothalamus and hindbrain; both also improve insulin secretion, and tirzepatide adds GIP receptor agonism. In STEP 1 (Wilding et al., NEJM 2021; 1,961 adults with obesity, no diabetes), semaglutide 2.4 mg produced −14.9% mean body weight at 68 weeks versus −2.4% on placebo. In SURMOUNT-1 (Jastreboff et al., NEJM 2022; n=2,539), tirzepatide reached −15.0%, −19.5%, and −20.9% at the 5, 10, and 15 mg doses over 72 weeks versus −3.1% on placebo.
Read those numbers with a caveat. Both trials enrolled people with obesity, not PCOS, and measured pounds — not acne, not cycles. Insulin resistance sits at the center of PCOS, and weight loss reliably improves it, so the mechanistic case that these drugs help is strong. But how much your androgenic symptoms move, and how fast, was not what these trials measured. That gap is exactly why you track.
What to track, monthly
Rate each from 0 (gone) to 10 (worst it’s been):
- Acne (jawline specifically)
- Hirsutism (chin, upper lip, jawline)
- Hair thinning (scalp)
- Cycle regularity
- Bloating
- Mood / anxiety
- Sleep quality
- Energy level
- Libido
- Brain fog
Add one objective measure: waist tape, same spot each time.
Symptoms move before the labs do
You can feel meaningfully better weeks before a testosterone or fasting-insulin panel confirms it, and a single lab draw can miss a real trend that a monthly chart makes obvious. The slow drift of acne from 8 to 5 is invisible day to day and unmistakable on paper. That early signal lets your clinician adjust without waiting for the next blood draw.
Log the nausea too
Nausea was the most common side effect in STEP 1, and it clustered during dose escalation. That is not a coincidence: it follows directly from delayed gastric emptying, which is why titration starts low and climbs slowly — 0.25 mg weekly to start, stepping roughly every 4 weeks (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), slower if side effects bite. Score nausea alongside your symptoms. If it is not fading as your dose holds steady, that is a titration conversation — a US-licensed clinician reviews every case and can slow the climb — not a reason to quit.
Protect the muscle underneath
Not all of the weight lost is fat. DXA substudies of GLP-1 trials show a meaningful fraction is lean mass; the long-term functional consequences of that are not yet well characterized, so treat this as a known risk with an unknown ceiling. The standard countermeasure is resistance training plus protein intake around 1.2–1.6 g/kg/day. Waist tape helps here — it tracks fat loss more honestly than the scale, which counts the muscle you would rather keep.
If you stop, it comes back
This is the part the before-and-after photos leave out. In STEP 4 (Rubino et al., JAMA 2021), people who stopped semaglutide at week 20 regained weight while those who continued kept losing. In SURMOUNT-4 (Aronne et al., JAMA 2024), after 36 weeks on tirzepatide, those switched to placebo regained about 14% of body weight over the next year while those who continued lost roughly 5.5% more. For PCOS this cuts twice: if weight is the lever on your symptoms, the symptoms follow the weight back up. Discontinuation without a maintenance plan usually reverses the gains.
What a GLP-1 won’t fix
Be honest about the ceiling. These drugs work on weight and insulin; they do not directly lower androgens. If jawline acne and hirsutism are your loudest symptoms, the tool for those is often an anti-androgen like spironolactone, sometimes running alongside the GLP-1. Your monthly chart is what tells you which symptoms are moving on their own and which need a second lever.
The simplest format, and the open question
A two-column note in your phone. Date on top, scores down the left, five minutes on the first of each month. Bring it to your visit — start here if you don’t have a clinician yet.
Here is what would change this advice: no large trial has tested whether GLP-1s improve PCOS symptoms — ovulation, hyperandrogenism — independently of the weight they take off, or whether any symptom gains hold once the drug stops. Until that trial runs, your monthly log is the data.
